Waters Corporation WAT

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Madison Investments, an investment advisor, released its second-quarter 2026 investor letter for the “Madison Mid Cap Fund”. You can download a copy of the letter here. U.S. stock market indices posted their strongest second-quarter performance since 2020, driven largely by enthusiasm for Artificial Intelligence. Nine of the ten largest companies in the Russell Midcap Index […]

Waters Corporation has outperformed the Health Care industry over the past year, and analysts are moderately optimistic about the stock’s prospects.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Waters Corporation (NYSE: WAT) today announced the global commercial launch of the BD FACSDiscover™ A7 Cell Analyzer, which uniquely combines exceptional spectral resolution and sensitivity with industry-leading standardization and ease-of-use features, making the power of advanced flow cytometry more accessible to researchers in academia and pharmaceutical settings, as well as in contract research organization (CRO) labs.

Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on Wednesday, September 23, 2026, at 12:00 PM BST (GMT+1) / 7:00 AM Eastern Time.

Waters stock has put in a strong multi year gain, yet the valuation signals are split, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model pointing to upside while the earnings multiple checks lean expensive. Over the past 3 years, Waters has returned about 53%, which puts more pressure on today’s entry price to be well supported by fundamentals. The company’s ability to keep converting its specialized analytical instruments and services into steady cash flow can...

Waters (WAT) stock is back in focus after the company reported Q2 2026 adjusted earnings of $3.05 per share and raised its full year guidance for organic revenue growth and adjusted earnings. At a share price of $413.56, Waters has posted a 30 day share price return of 4.41% and a 90 day share price return of 13.19%. The 1 year total shareholder return of 38% and 3 year total shareholder return of 53% point to building momentum supported by upgraded guidance and recent leadership...

Waters Corporation recently announced that Senior Vice President of the Waters Analytical Sciences Division, Robert L. Carpio III, resigned in August 2026, with Tina Wu, previously head of the Materials Sciences Division and President, China, stepping into the role after more than two decades of global leadership experience at DuPont. Around the same time, Waters reported very large year-over-year revenue growth in the second quarter of 2026 and raised its full-year guidance, underlining the...

Although Waters Corporation has exceeded the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Waters Corporation (NYSE:WAT) and the rest of the research tools & consumables stocks fared in Q2.